1.	Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 Administered in Healthy Adolescents. Phase: Phase IV Type: Prevention Status: Active Age: 12 to 15 Sponsor: Pharmaceutical / Industry Protocol IDs: 106636, NCT00534638
2.	Evaluate Safety of a Vaccine Against Cervical Cancer (HPV-16/18 L1/AS04) in Healthy Filipino Females Aged 10 Yrs & Above Phase: Phase IV Type: Prevention Status: Active Age: 10 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 108160, NCT00730847
3.	Safety Study of Cervarix® in Females Aged 18-25 Years in Scotland. Phase: Phase IV Type: Prevention Status: Approved-not yet active Age: 18 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: 111103, NCT00880438
4.	Phase III Randomized Study of Diindolylmethane in Patients With Low-Grade Cervical Cytological Abnormalities Phase: Phase III Type: Prevention Status: Active Age: Not specified Sponsor: Other Protocol IDs: CRUK-CRISP-1, ISRCTN47437431, EU-20717, NCT00462813
5.	Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine 580299 in Healthy Females 10 - 25 Years of Age. Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 10 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: 106069, NCT00481767
6.	Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects Phase: Phase III Type: Prevention Status: Active Age: 18 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: 107638, NCT00779766
7.	Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US Phase: Phase III Type: Prevention Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 111955, NCT00799825
8.	Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand Phase: Phase III Type: Prevention Status: Active Age: 26 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 111758, NCT00849381
9.	Phase II Randomized Study of Celecoxib in Patients With Cervical Intraepithelial Neoplasia (CIN) 2/3 or 3 Phase: Phase II Type: Prevention, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: GOG-0207, NCT00081263
10.	Phase II Randomized Study of Green Tea Extract (Polyphenon E®) for the Prevention of Cervical Cancer in Patients With Human Papillomavirus (HPV) and Low-Grade Cervical Intraepithelial Neoplasia (CIN 1) Phase: Phase II Type: Prevention Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UARIZ-UAZ03-1-02, UARIZ-HSC-0540, UAZ03-1-02, NCT00303823
11.	Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women Phase: Phase II Type: Prevention Status: Active Age: 16 to 26 Sponsor: Pharmaceutical / Industry Protocol IDs: 2007_538, V503-001, NCT00543543
12.	Phase II Study of Folic Acid Supplementation in Women Infected With HPV-16 and Diagnosed With Grade 1 or Less Cervical Intraepithelial Neoplasia Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 19 and over Sponsor: NCI Protocol IDs: UAB-F060511015, F060511015, UAB-IRB0000196, NCT00703196
13.	Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix TM) in HIV Infected Females Phase: Phase II Type: Prevention Status: Active Age: 18 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: 107863, NCT00586339
14.	Phase I Study of pNGVL4a-Sig/E7(detox)/HSP70 DNA Vaccine and TA-HPV Vaccine With or Without Imiquimod in Patients With Human Papillomavirus 16-Positive Grade 3 Cervical Intraepithelial Neoplasia Phase: Phase I Type: Biomarker/Laboratory analysis, Prevention, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: JHOC-J0656, J0656, NA_00002176, NCT00788164
15.	Phase I Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Positive and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults Phase: Phase I Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 12 to 26 Sponsor: NCI Protocol IDs: NCI-09-C-0024, 09-C-0024, NCI-P07277, NCT00798265
16.	Randomized Pilot Study of Zoledronate in Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 Phase: No phase specified Type: Prevention, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UCSF-03421, UCSF-H7810-25693-01, UCSF-H7810-25693-02A, NCT00278434
17.	Randomized Study of Health Education Counseling With Versus Without Bupropion Hydrochloride in African-Americans Who Are Light Smokers Phase: No phase specified Type: Behavioral study, Biomarker/Laboratory analysis, Educational/Counseling/Training, Prevention Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: KUMC-HSC-10332, 10332, KUMC-070313, NCT00666978
18.	Pilot Study of the Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Virus-Like-Particle Recombinant Vaccine in HIV-Positive Women in India Phase: No phase specified Type: Biomarker/Laboratory analysis, Prevention Status: Approved-not yet active Age: 18 and over Sponsor: NCI Protocol IDs: AMC-054, AMC-054, NCT00667563
19.	Acceptance of Human Papillomavirus Vaccination in Postpartum Women Phase: No phase specified Type: Prevention Status: Approved-not yet active Age: 18 to 26 Sponsor: Other Protocol IDs: IRB-AAAD1877, NCT00730704
20.	Randomized Study of Varenicline Versus Combination Nicotine Replacement Therapy Using Nicotine Patch and Gum in Smokers Participating in a Methadone Maintenance Treatment Program Phase: No phase specified Type: Behavioral study, Prevention Status: Active Age: Over 18 Sponsor: Other Protocol IDs: BUTLER-0807-004, 0807-004, NCT00790569
21.	Alternate Dosing Schedules Study for HPV Vaccine Phase: No phase specified Type: Prevention Status: Active Age: 9 to 15 Sponsor: Other Protocol IDs: Pro00014388, CDC#U36/CCU319276 CFDA 93.283, NCT00862810